Parkinson's Disease Psychosis Clinical Trial
This study will evaluate the safety and efficacy of two dose levels of pimavanserin (ACP-103) compared to placebo in patients with Parkinson's disease psychosis.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06068465 -
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
|
Phase 3 | |
| Recruiting |
NCT04373317 -
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
|
Phase 4 | |
| Completed |
NCT01518309 -
An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients
|
Phase 2 | |
| Completed |
NCT00477672 -
A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
|
Phase 3 | |
| Completed |
NCT01174004 -
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
|
Phase 3 | |
| Completed |
NCT00550238 -
A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
|
Phase 3 | |
| Recruiting |
NCT05590637 -
Comparing Antipsychotic Medications in LBD Over Time
|
Phase 4 | |
| Approved for marketing |
NCT02762591 -
Expanded Access of Pimavanserin for Patients With PD Psychosis
|
N/A |